Pharma BD Deal Intelligence
A $1.5B stock-for-stock deal for FluMist that never got close to its billion-dollar thesis: peak sales limped to ~$21-55M through the mid-2000s, and CDC/ACIP later pulled its pediatric recommendation over near-zero efficacy data.
FluMist was pitched as a $1B+ blockbuster nasal-flu vaccine; it took nearly two decades and CDC reversed course on its efficacy in children along the way — the deal never came close to justifying its $1.5-1.6B price tag.
Full analysis, sources & comparables →Form 425 details the stock-for-stock exchange offer of 1.075 MedImmune shares per Aviron share, presenting the FluMist-driven combination favorably to Aviron…
By acquiring Aviron, MedImmune gains rights to FluMist, an inhaled flu vaccine expected to gain regulatory approval in the second half of next year. FluMist…
MedImmune purchased Aviron in 2002, one year before FDA approval, and commercialized the product under the FluMist brand. The vaccine uses a cold-adapted…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
MedImmune-Aviron stock-for-stock deal; 1.075 MedImmune shares per Aviron share at $47.41/share. Brought in FluMist intranasal flu vaccine. Closed 2002-01-10.
FluMist was pitched as a $1B+ blockbuster nasal-flu vaccine; it took nearly two decades and CDC reversed course on its efficacy in children along the way — the deal never came close to justifying its $1.5-1.6B price tag.
Assessment window: 15yr post-close.
40M US cases/yr
Seasonal influenza is a contagious respiratory illness caused by influenza A and B viruses, infecting tens of millions of Americans each year and causing 470,000-710,000 hospitalizations and 28,000-45,000 deaths annually. Vaccination is the primary prevention strategy, traditionally delivered by intramuscular injection.
At deal time (2001-2002), the US influenza vaccine market was dominated by inactivated injected vaccines from Aventis Pasteur (Fluzone), Wyeth-Ayerst (FluShield) and Chiron/Evans (Fluvirin). Aviron's FluMist was a differentiated live attenuated influenza vaccine (LAIV) administered as a nasal spray rather than injection - a needle-free convenience play targeting healthy children and working-age adults. The acquisition gave MedImmune its first commercial-stage prophylactic vaccine to complement Synagis (RSV mAb) and positioned the company as a pure-play vaccine and biologics franchise. Analysts saw FluMist as a potential blockbuster: MedImmune CEO David Mott projected >$1B peak sales, and the Wall Street narrative pre-deal had nearly doubled MedImmune's stock on FluMist anticipation. FDA approved LAIV/FluMist in June 2003 - 18 months after deal close - though uptake disappointed versus expectations due to age restrictions (initially 5-49 healthy only) and refrigeration logistics. The deal cemented MedImmune as a top-3 US biotech and set the stage for AstraZeneca's $15.6B 2007 takeout. Reference: https://en.wikipedia.org/wiki/FluMist
| Deal | Year | Value | Outcome |
|---|---|---|---|
| MedImmune Inc. / Aviron (this deal) | 2001 | $1.5B | 36 |
| MedImmune Inc. / Aviron | 2002 | $1.5B | 28 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
← Browse all deals · How we score deals
More: 2001 deals